Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹9,972 Cr
Revenue (TTM)
₹1,196 Cr
Net Profit (TTM)
₹149 Cr
ROE
27.5 %
ROCE
32.6 %
P/E Ratio
66.7
P/B Ratio
14.2
Industry P/E
28.31
EV/EBITDA
40.5
Div. Yield
0.4 %
Debt to Equity
0.1
Book Value
₹99.1
EPS
₹24.4
Face value
10
Shares outstanding
61,160,088
CFO
₹221.86 Cr
EBITDA
₹645.89 Cr
Net Profit
₹394.41 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CORONA Remedies
| 17.8 | 3.4 | 16.3 | -- | -- | -- | -- |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CORONA Remedies
|
1,631.1 | 9,972.2 | 1,196.4 | 149.4 | -- | 27.5 | 66.7 | 14.2 |
| 3,056.6 | 38,176.6 | 5,201.6 | 1,014.6 | 22.9 | 25 | 37.6 | 8.3 | |
| 8,483.5 | 21,239.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 105.7 | 25.5 | |
| 1,648.2 | 12,536.2 | 2,089.5 | 622.0 | 31.3 | 20.4 | 20.4 | 3.8 | |
| 1,308.1 | 18,156.7 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.1 | 5.0 | |
| 2,118.0 | 33,968.6 | 4,193.0 | 753.8 | 22.7 | 20.8 | 45.1 | 8.5 | |
| 4,818.0 | 22,063.4 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.8 | 5.5 | |
| 4,939.8 | 8,194.5 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.9 | 11.8 | |
| 3,460.8 | 7,974.5 | 1,837.4 | 326.7 | 24.7 | 45.3 | 24.4 | 10.6 | |
| 907.1 | 8,342.6 | 4,725.6 | 528.7 | 14.9 | 20.7 | 16.3 | 2.8 |
--
Incorporated
2004
Chairman
Kirtikumar Laxmidas Mehta
Managing Director
Niravkumar Kirtikumar Mehta
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about CORONA Remedies Ltd’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of CORONA Remedies Ltd is ₹1,631.10 (NSE) and ₹1,630.50 (BSE) as of 18-Mar-2026 IST. CORONA Remedies Ltd has given a return of --% in the last 1 years.
The P/E ratio of CORONA Remedies Ltd is 66.73 times as on 18-Mar-2026, a 136 premium to its peers’ median range of 28.31 times.
The P/B ratio of CORONA Remedies Ltd is 14.23 times as on 18-Mar-2026, a 193 premium to its peers’ median range of 4.85 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
0.00
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of CORONA Remedies Ltd are Rs 1,699.00 and Rs 1,336.60 as of 19-Mar-2026.
CORONA Remedies Ltd has a market capitalisation of ₹ 9,972 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in CORONA Remedies Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹70.10
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.